

Contents

List of Contributors XIII

Preface XVII

Part One Medicinal Chemistry 1

- 1 **Organometallic Complexes as Enzyme Inhibitors: A Conceptual Overview** 3
Philipp Anstaett and Gilles Gasser
 - 1.1 Introduction 3
 - 1.2 Organometallic Compounds as Inert Structural Scaffolds for Enzyme Inhibition 3
 - 1.3 Organometallic Compounds Targeting Specific Protein Residues 11
 - 1.4 The Bioisosteric Substitution 14
 - 1.5 Novel Mechanisms of Enzyme Inhibition with Organometallic Compounds 19
 - 1.6 Organometallic Compounds as Cargo Delivers of Enzyme Inhibitors 25
 - 1.7 Organometallic Enzyme Inhibitors for Theranostic Purposes 30
 - 1.8 Conclusion 34

Acknowledgments 35
Abbreviations 35
References 36

- 2 **The Biological Target Potential of Organometallic Steroids** 43
Gérard Jaouen, Siden Top, and Michael J. McGlinchey
 - 2.1 Introductory Note on Nuclear Receptors 43
 - 2.1.1 Early History 43
 - 2.1.2 Primary Structure of Nuclear Receptors 44
 - 2.1.3 Estrogen Receptors 45
 - 2.1.4 Androgens 45
 - 2.1.5 Glucocorticoids 46
 - 2.1.6 Progesterone and Progestogens 46

2.1.7	Mineralocorticoids and Aldosterone	46
2.1.8	Selective Modulators of Nuclear Receptors	47
2.1.8.1	Selective Estrogen Receptor Modulators (SERMs)	47
2.1.8.2	Selective Androgen Receptor Modulators (SARMs)	48
2.1.8.3	Selective Progesterone Receptor Modulators (SPRMs)	48
2.1.9	Mechanism of Action of Nuclear Receptors	48
2.1.10	Endocrine Disruptors	50
2.2	Steroids and Organometallics: An Overview of the Transitional Period from the Use of Organometallics in Synthesis to the Emergence of Bioorganometallics	53
2.2.1	Early Examples of Organometallic Estradiol Derivatives with Biological Potential: Modified Hormone Shown to Bind to Estrogen Receptor α	56
2.2.2	Examples of Estrogens Modified by Organometallics at the 11 β -Position	62
2.2.3	Targeting Prostate Cancer with Organometallic Androgens and Antiandrogens	64
2.2.4	Approach Toward Organometallic Radiopharmaceuticals	66
2.2.4.1	Steroidal Derivatives	66
2.2.4.2	Nonsteroidal Complexes	73
2.3	Epilog	75
	Acknowledgments	76
	References	76
3	Chirality in Organometallic Anticancer Complexes	85
	<i>Maria J. Romero and Peter J. Sadler</i>	
3.1	Introduction	85
3.2	Chirality in Arene Complexes	87
3.3	CIP System for the Nomenclature of Chiral-at-Metal Arene Complexes	89
3.4	Chiral Organometallic Complexes as Anticancer Agents	90
3.4.1	Chiral Carbene Complexes	90
3.4.2	Chiral Metallocene Complexes	91
3.4.3	Chiral Half-Sandwich Arene Complexes	93
3.4.4	Chirality at Metal in Supramolecular Complexes	97
3.5	Half-Sandwich Complexes with Chiral Metal Centers	99
3.5.1	Factors Influencing the Chirality at the Metal Center	100
3.5.1.1	Use of Chiral Ligands for Chiral Resolution at the Metal Center: Diastereoisomerism	100
3.5.1.2	CH- π Interactions: β -Phenyl Effect and Hydrogen Bond Interactions	101
3.5.1.3	Effect of the Temperature, Solvent and Ligands on the Metal Configuration	103

- 3.6 Conclusions 110
Acknowledgments 111
References 111
- 4 Gold Organometallics with Biological Properties 117**
Maria Agostina Cinellu, Ingo Ott, and Angela Casini
- 4.1 Introduction: The Use of Gold in Medicine 117
- 4.2 Anticancer Gold Organometallics and Proposed Biological Targets 117
- 4.2.1 Cyclometalated Gold(III) Complexes with C,N-Donor Ligands 121
- 4.2.1.1 Types of Cycloaurated Complexes, Synthetic Methods, and Reactivity 122
- 4.2.1.2 Cycloaurated Complexes with Biological Activities 125
- 4.2.2 Gold N-Heterocyclic Carbene (NHC) Complexes 129
- 4.2.3 Gold Alkynyl Complexes 132
- 4.3 Conclusions and Perspectives 134
List of Abbreviations 135
References 135
- 5 On the Molecular Mechanisms of the Antimalarial Action of Ferroquine 141**
Faustine Dubar and Christophe Biot
- 5.1 History and Development 141
- 5.2 Mechanism(s) of Action of 4-Aminoquinoline Antimalarials 141
- 5.3 Mechanism(s) of Action of Ferroquine as an Antimalarial 144
- 5.3.1 Antimalarial Activity 144
- 5.3.2 Metabolic Pathway of Ferroquine 144
- 5.3.3 Redox Properties of FQ 144
- 5.3.4 Basic Properties and Accumulation 147
- 5.3.5 Importance of Redox Properties of Ferrocene on Antimalarial Activity of FQ 155
- 5.3.6 Inhibition of Hemozoin Formation 157
- 5.4 Conclusion 160
Acknowledgments 161
List of Abbreviations 161
References 161
- 6 Metal Carbonyl Prodrugs: CO Delivery and Beyond 165**
Carlos C. Romão and Helena L.A. Vieira
- 6.1 Introducing CO in Biology 165
- 6.1.1 Origin 165
- 6.1.2 Biological Action and Targets of CO 166
- 6.1.3 Therapeutic Outlook 166
- 6.1.4 Measuring CO in Biology 167
- 6.2 Therapeutic Delivery of CO 167

- 6.2.1 CO Gas and Inhalation 167
- 6.2.2 Prodrugs for CO Delivery: CO-Releasing Molecules (CORM) 168
 - 6.2.2.1 Definitions and Concept 168
- 6.2.3 Early CORMs 169
 - 6.2.3.1 Nonmetal-Based CORMs 169
 - 6.2.3.2 Metal Carbonyl-Based CORMs 169
- 6.2.4 The Chemical Biology of Early CORMs 171
 - 6.2.4.1 $[\text{Ru}(\text{CO})_3]^{2+}$ -Based CORMs 171
 - 6.2.4.2 $[\text{Mo}(\text{CO})_n]$ -Based CORMs 176
 - 6.2.4.3 Miscellaneous Biologically Significant Observations on Early-Stage CORMs 177
- 6.3 Biological and Therapeutic Results Obtained with the Early-Stage CORMs 178
 - 6.3.1 CORM and Inflammatory Response 178
 - 6.3.2 Cardioprotective Effects of CORM 180
 - 6.3.3 Central Nervous System and CORMs 180
 - 6.3.4 Transplantation 181
 - 6.3.5 Bactericide Effects of CORMs 181
 - 6.3.6 CORMs: Tissue Regeneration and Modulation of Cell Proliferation/Differentiation 182
 - 6.3.7 CORMs and Cancer Therapy? 182
- 6.4 Beyond the Early-Stage CORMs: Strategies for Finding New Candidates 183
 - 6.4.1 Evaluation of CO Release from CORMs 184
 - 6.4.2 Light Activated or photoCORMs 185
 - 6.4.3 Chemically Activated CORMs 187
 - 6.4.4 Bioactivated or Enzyme-Triggered CORMs (ET-CORMs) 191
- 6.5 Intracellular Detection of CORMs, Mechanistic Studies, and Other Unanswered Questions 192
- 6.6 Designing Pharmacologically Useful, Drug-like CORMs 193
 - 6.6.1 The First Drug-like CORM 195
- 6.7 Final Remarks and Perspectives 196
 - List of Abbreviations 196
 - References 198
- 7 Dinitrosyl Iron Complexes with Natural Thiol-Containing Ligands: Physicochemistry, Biology, and Medicine 203**
Anatoly F. Vanin
 - 7.1 Introduction 203
 - 7.2 The History of Detection and Identification of DNIC with Thiol-Containing Ligands in Microorganisms and Animal Tissues 204
 - 7.3 Physicochemistry of DNIC with Natural Thiol-Containing Ligands 208

- 7.3.1 Mono- and Binuclear forms of DNIC with Natural Thiol-Containing Ligands 208
- 7.3.2 Two Approaches to the Synthesis of DNIC with Natural Thiol-Containing Ligands 209
- 7.3.3 Mechanisms of Formation of DNIC with Natural Thiol-Containing Ligands 210
- 7.3.4 The Electronic and Spatial Structures of DNIC with Thiol-Containing Ligands 212
- 7.3.5 DNIC with Thiol-Containing Ligands as NO and NO⁺ Donors 213
- 7.4 Biological Effects of DNIC with Thiol-Containing Ligands 219
 - 7.4.1 S-Nitrosating Effect of DNIC with Thiol-Containing Ligands 219
 - 7.4.2 Vasodilator and Hypotensive Effects of DNIC with Thiol-Containing Ligands 220
 - 7.4.3 Inhibiting Effect of DNIC with Thiol-Containing Ligands on Platelet Aggregation 224
 - 7.4.4 DNIC with Thiol-Containing Ligands Increase Erythrocyte Elasticity 225
 - 7.4.5 DNIC with Thiol-Containing Ligands Accelerate Skin Wound Healing in Animals 225
 - 7.4.6 Erective Activity of DNIC 226
 - 7.4.7 - DNIC and Apoptosis 227
 - 7.4.8 DNIC with Glutathione Inhibits the Development of Experimental Endometriosis in Rats 230
 - 7.4.9 Other Examples of Biological Effects of DNIC with Thiol-Containing Ligands 232
- 7.5 DNIC with Thiol-Containing Ligands as a Basis in the Design of Drugs with a Broad Range of Therapeutic Activities 233
 - List of Abbreviations 234
 - Acknowledgments 235
 - References 235

Part Two Metalloproteins, Catalysis, and Energy Production 239

- 8 The Bioorganometallic Chemistry of Hydrogenase 241**
Ryan D. Bethel and Marcetta Y. Darensbourg
- 8.1 Introduction 241
 - 8.1.1 Hydrogenase 241
 - 8.1.2 The Chemistry of Hydrogen 243
 - 8.1.3 Dihydrogen Metal Complexes 244
 - 8.1.4 First Coordination Sphere Ligands 247
- 8.2 Structure and Function 247
 - 8.2.1 The Active Sites of the Hydrogenases 247
 - 8.2.1.1 [NiFe]- and [FeFe]-Hydrogenase 247
 - 8.2.1.2 [Fe]-Hydrogenase 250

8.2.2	The Mechanisms of the Hydrogenases	251
8.3	Natural Biosynthesis and Synthetic Analogs of the Active Sites	253
8.3.1	Natural Biosynthesis of Hydrogenase Active Sites	253
8.3.1.1	Biosynthesis of [NiFe]-Hydrogenase	254
8.3.1.2	Biosynthesis of [FeFe]-Hydrogenase	255
8.3.2	Synthetic Analogs	256
8.3.2.1	Models of the [NiFe]-Hydrogenase Active Site	256
8.3.2.2	Models of the [FeFe]-Hydrogenase Active Site	259
8.3.2.3	Models of the [Fe]-Hydrogenase Active Site	263
8.4	Comments and Conclusion	265
	References	268
9	Bio-Organometallic Systems for the Hydrogen Economy: Engineering of Electrode Materials and Light-Driven Devices	273
	<i>Murielle Chavarot-Kerlidou, Pascale Chenevier, and Vincent Artero</i>	
9.1	Introduction	273
9.2	Electrode Materials for Hydrogen Evolution and Uptake	274
9.2.1	Electrode Materials-Based on Hydrogenases	274
9.2.2	Hydrogen Fuel Cell Electrodes Based on Hydrogenases	277
9.2.3	Electrode Materials Based on Bio-inspired Molecular Catalysts	279
9.2.3.1	Covalent Attachment of Catalyst to Electrode Material	279
9.2.3.2	Noncovalent Attachment of Catalyst to Electrode Material via π - π Stacking Interaction	283
9.3	Light-Driven Systems for Hydrogen Evolution	284
9.3.1	Biological and Biohybrid Systems	286
9.3.2	Bio-inspired Catalysis Approaches	288
9.3.2.1	Iron-Based Catalysts	289
9.3.2.2	Nickel-Based Catalysts	294
9.3.2.3	First Approaches toward Molecular-Based Photoelectrodes	295
9.4	Artificial Photosynthetic Systems	297
9.5	Summary and Conclusions	298
	List of Abbreviations	298
	References	299
10	Artificial Metalloenzymes Containing an Organometallic Active Site	305
	<i>Akira Onoda, Takashi Hayashi, and Michèle Salmain</i>	
10.1	Introduction	305
10.2	Dative Anchoring	306
10.2.1	Metalloproteins as Protein Hosts	306
10.2.2	Other Protein Hosts	313
10.3	Supramolecular Anchoring	316
10.3.1	(Strept)avidin as Protein Hosts	316
10.3.2	Antibodies as Protein Hosts	319
10.3.3	Other Protein Hosts	320

- 10.4 Covalent Anchoring 321
- 10.5 Mixed Anchoring Modes 326
- 10.5.1 Supramolecular + Covalent Anchoring 326
- 10.5.2 Supramolecular + Dative Anchoring 327
- 10.5.3 Dative + Covalent Anchoring 327
- 10.6 Peptide Scaffolds 328
- 10.7 Summary and Outlook 332
- List of Abbreviations 332
- References 333

Part Three Bioanalysis 339

- 11 **Organometallic Bioprobes for Cellular Imaging** 341
Emanuela Licandro, Monica Panigati, Michèle Salmain, and Anne Vessières
- 11.1 Introduction 341
- 11.1.1 Definition of Organometallic Bioprobes 342
- 11.1.2 Comparison of Different Imaging Techniques 343
- 11.2 Luminescence 346
- 11.2.1 Photophysical Properties of an Ideal Fluorophore for Cell Imaging 347
- 11.2.2 Emission Properties of the Main Classes of Organometallic Complexes 348
- 11.2.3 Other Advantages in the Use of Organometallic Complexes for Luminescence Imaging 351
- 11.2.4 Time-Resolved Techniques 352
- 11.2.5 Rhenium 352
- 11.2.5.1 Mononuclear Rhenium Complexes 352
- 11.2.5.2 Dinuclear Rhenium Complexes 360
- 11.2.5.3 Bimodal Rhenium Agents 362
- 11.2.6 Iridium 362
- 11.2.6.1 Simple Organometallic Iridium Complexes 362
- 11.2.6.2 Iridium Bioconjugates 365
- 11.2.7 Rhodium 367
- 11.2.7.1 Simple Organometallic Rhodium Complexes 367
- 11.2.7.2 Rhodium Bioconjugates 367
- 11.2.8 Platinum 368
- 11.2.8.1 Confocal Fluorescence Microscopy Imaging with Platinum Complexes with One or Two Photon Excitation 368
- 11.2.8.2 Time-Resolved Imaging with Platinum Complexes 370
- 11.2.9 Gold 371
- 11.2.9.1 Simple Organometallic Gold Complexes 371
- 11.2.9.2 Gold Bioconjugates 372
- 11.3 Vibrational Spectroscopy 372
- 11.3.1 Infrared Microscopy 374

11.3.2	Bimodal Detection (by Infrared and Luminescence)	377
11.3.3	AFM-IR Spectroscopy	378
11.3.4	Raman Spectromicroscopy	379
11.4	Miscellaneous	381
11.4.1	Nanoimaging Based on X-Ray Fluorescence	381
11.4.2	Ferrocene-Based Fluorescent Probe	382
11.5	Conclusions	383
	Acknowledgments	384
	Abbreviations	384
	References	386

Index	393
--------------	-----